These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15051689)

  • 1. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity.
    Wooltorton E
    CMAJ; 2004 Mar; 170(7):1091. PubMed ID: 15051689
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
    Rivero A; Mira JA; Pineda JA
    J Antimicrob Chemother; 2007 Mar; 59(3):342-6. PubMed ID: 17255142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
    Sanne I; Mommeja-Marin H; Hinkle J; Bartlett JA; Lederman MM; Maartens G; Wakeford C; Shaw A; Quinn J; Gish RG; Rousseau F
    J Infect Dis; 2005 Mar; 191(6):825-9. PubMed ID: 15717255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
    HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
    Stern JO; Robinson PA; Love J; Lanes S; Imperiale MS; Mayers DL
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S21-33. PubMed ID: 14562855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen.
    Johnson S; Chan J; Bennett CL
    Ann Intern Med; 2002 Jul; 137(2):146-7. PubMed ID: 12118982
    [No Abstract]   [Full Text] [Related]  

  • 8. Spanish study looks at the effect of nevirapine on the liver.
    TreatmentUpdate; 2001 Jul; 13(3):4-5. PubMed ID: 11569988
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
    De Requena DG; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):555-9. PubMed ID: 15989460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
    Phillips E; Bartlett JA; Sanne I; Lederman MM; Hinkle J; Rousseau F; Dunn D; Pavlos R; James I; Mallal SA; Haas DW
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):e55-7. PubMed ID: 23328091
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
    Palmon R; Koo BC; Shoultz DA; Dieterich DT
    J Acquir Immune Defic Syndr; 2002 Apr; 29(4):340-5. PubMed ID: 11917237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
    Bundow D; Rosoff L; Aboulafia DM
    AIDS Read; 2001 Nov; 11(11):577-80. PubMed ID: 11789021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 18. RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity.
    Walubo A; Barr S; Abraham AM
    Methods Find Exp Clin Pharmacol; 2006 Sep; 28(7):423-31. PubMed ID: 17003847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine-induced hepatitis: a case series and review of the literature.
    Piliero PJ; Purdy B
    AIDS Read; 2001 Jul; 11(7):379-82. PubMed ID: 11494710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatitis and nevirapine].
    Palacios R; Santos J; González M; Márquez M
    Med Clin (Barc); 2000 Apr; 114(15):597-8. PubMed ID: 10846681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.